HMGCR emerges as a promising target for precision cancer therapies + + +

HMGCR emerges as a promising target for precision cancer therapies https://www.news-medical.net/news/20260805/HMGCR-emerges-as-a-promising-target-for-precision-cancer-therapies.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=prostate_cancer_newsletter_10_august_2026 HMGCR emerges as a promising target for precision cancer therapiesA growing body of evidence is reshaping how scientists and clinicians understand the role of cancer metabolism, placing the enzyme HMGCR at the center of a rapidly evolving therapeutic landscape. Tuft cell-like cancers exhibit unique biological characteristics across multiple organs https://www.news-medical.net/news/20260806/Tuft-cell-like-cancers-across-multiple-organs-exhibit-unique-biological-characteristics.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=prostate_cancer_newsletter_10_august_2026 Tuft cell-like cancers exhibit unique biological characteristics across multiple organsA growing body of evidence suggests that a rare epithelial cell type known as the tuft cell may play a far more significant role in cancer than previously recognized. Early radionuclide therapy delays progression in metastatic prostate cancer https://www.news-medical.net/news/20260806/Early-radionuclide-therapy-delays-progression-in-metastatic-prostate-cancer.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=prostate_cancer_newsletter_10_august_2026 Earlier use of a targeted radionuclide therapy delays metastatic prostate cancer progression when administered as part of a trio of drugs, according to a phase 3 clinical trial led by Weill Cornell Medicine, NewYork-Presbyterian, Memorial Sloan Kettering Cancer Center and investigators at several other institutions worldwide.